HUTCHMED Initiates And Doses First Patient In Phase III Trial Of HMPL-760 For R/R DLBC Lymphoma

AI Briefing

• – HUTCHMED initiates Phase III trial of HMPL-760 for relapsed/refractory DLBC lymphoma.
• – The trial combines HMPL-760 with R-GemOx for patients with DLBCL in China.
• – This is HUTCHMED's first Phase III trial for HMPL-760.